J. Perry, W. Mason, K. Belanger, P. Kavan, D. Fulton, J. Easaw, S

Slides:

Advertisements

Similar presentations

Palumbo A et al. Proc ASH 2013;Abstract 536.

Advertisements

1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.

Palumbo A et al. Proc ASH 2012;Abstract 446.

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

Phase III studies of Xeloda® in colorectal cancer (CRC)

Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.

Methods Patients: Unresectable GBM PS 0-2, MMS≥25 Centralized radiological Review RANO criteria Centralized pathological Review: MGMT tissue & MGMT serum.

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated,

Capecitabine versus Bolus 5-FU/Leucovorin as Adjuvant Therapy for Colon Cancer: X-ACT Trial Results James Cassidy, MD Colorectal Cancer Update Think Tank.

Eastern cooperative oncology group Impact of Bevacizumab Dose Reduction on Clinical Outcomes for Patients Treated on the Eastern Cooperative Oncology Group’s.

1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.

Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.

Consolidation treatment with Y 90 Ibritumomab Tiuxetan after R-CHOP induction in high-risk patients with Follicular Lymphoma (FL) (GOTEL-FL1LC): a multicentric,

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

GBM – Oncological Management Dr H Lord Consultant Clinical Oncologist.

Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

EORTC OSN/CTOS11 Safety of Caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Final.

1 Presented by Martin Cohen, M.D. at the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

1 NDA Clofarabine Cl-F-Ara-A Presented by Martin Cohen, M.D. at the December 01, 2004 meeting of the Oncologic Drugs Advisory Committee meeting.

1 NDA Nelarabine. 2 Proposed Indication Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (ALL) and.

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory.

Use of Bevacizumab in anticoagulated recurrent glioblastoma multiforme patients: An Australian experience Adrian Lee 1,2,3,4, Marina Kastelan 4,5, Helen.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.

R3 이운주/Prof 맹치훈. Introduction Pancreatic adenocarcinoma is most lethal cancer, with a 5-year survival rate of less than 5%. Relapsed occurs in 80-85%

Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.

Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Alessandra Gennari, MD PhD

Palumbo A et al. Proc ASH 2012;Abstract 200.

STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.

Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma

Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Table 1 Baseline patient characteristics

Intervista a Angelo Delmonte

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Metastatic Renal Cell Carcinoma

Barrios C et al. SABCS 2009;Abstract 46.

Fenaux P et al. Lancet Oncol 2009;10(3):

Stupp Trial: Improved survival with TMZ Chemotherapy

Niesvizky R et al. Proc ASH 2010;Abstract 619.

A Report from ECCO 14 Oral Chemotherapy in Breast Cancer

Coiffier B et al. Proc ASH 2010;Abstract 857.

CTCL: INNOVATIVE TREATMENTS GEMCITABINE

Fowler NH et al. Proc ASH 2011;Abstract 99.

First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

FDA-Approved PI3K Inhibitors for CLL and FL

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

1University Hospital Gasthuisberg, Leuven, Belgium;

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Presentation transcript:

Daily Temozolomide Following Failure of Prior RT + TMZ for GBM: Update on the RESCUE Study J. Perry, W. Mason, K. Belanger, P. Kavan, D. Fulton, J. Easaw, S. Kirby, D. MacDonald, C. Shields and J.-F. Pouliot

42-year-old woman with GBM treated with daily temozolomide at first relapse on the NCIC-CTG/EORTC Trial PD: 9 mo after RT/TMZ, 6 cycles adjuvant TMZ CR after 4 cycles continuous TMZ 50 mg/m2

Temozolomide Dose-intense Rescue

RESCUE Study Design

Study Objectives

Main Inclusion Criteria

Main Exclusion Criteria

Demographics

Six-month Progression-free Survival

Progression-free Survival (by subgroup)

Non hematological Toxicity (worst grade) *All AEs irrespective of causality incidence >2% No Grade 4 toxicity reported at this point in time

Hematological Toxicity (worsened grade since baseline)

Baseline Hematological Abnormalities (all patients)

Conclusions